Response to primary chemotherapy in breast cancer patients with tumors not expressing estrogen and progesterone receptors

Annals of Oncology

Volumn 11, Issue 8, 2000, Pages 1057-1059

  Colleoni, M ^a   Minchella, I ^a   Mazzarol, G ^a   Nole F ^a   Peruzzotti, G ^a   Rocca, A ^a   Viale, G ^a   Orlando, L ^a   Ferretti, G ^a   Curigliano, G ^a   Veronesi, P ^a   Intra, M ^a   Goldhirsch, A ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

Breast cancer; Estrogen receptor; Preoperative chemotherapy; Progesterone receptor

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; FOLINIC ACID; NAVELBINE; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER REGRESSION; CHEMOSENSITIVITY; CHEMOTHERAPY; DRUG RESPONSE; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; TREATMENT OUTCOME; TUMOR VOLUME;

EID: 0033798028     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008334404825     Document Type: Article

References (15)

1. Primary chemotherapy in surgically resectable breast cancer
2. Effects of primary chemotherapy in conservative treatment of breast cancer patients with operable tumors larger than 3 cm: Results of a randomized trial in a single centre
3. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer
4. Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer
5. Primary chemotherapy in operable breast cancer: Eight-year experience at the Milan Cancer Institute
6. Clinical prognostic and predictive factors for primary chemotherapy in operable breast cancer
7. Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas
8. Primary chemotherapy in breast invasive carcinoma Predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erb B-2, MiB1, pS2 and GST
9. Prediction of response to primary chemotherapy for operable breast cancer
10. Early start of adjuvant chemotherapy may improve treatment outcome for premenopausal breast cancer patients with tumors not expressing estrogen receptors
11. In vitro adiamycin sensitivity test and hormonal receptors in primary breast cancer
12. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer
13. Influence of the interval between primary tumor removal and chemotherapy on kinetics and growth of metastasis
14. Control of human breast cancer by estrogens, growth factors, and oncogenes
15. Possible role of cell kinetics in prediction of the response to cancer therapy